Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
78567.000.6616%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Amneal Pharmaceuticals Inc

AMRXNASDAQ
Trade with Public
Trade with Public
$17.44
-0.43-2.41%
At close: Sep 4, 5:00 PM EST
$17.44
N/A
After Hours: Sep 4, 4:34 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Amneal Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Amneal Pharmaceuticals (AMRX).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

6Buy
Consensus RatingOverweight# Analysts6Avg. Consensus PT$15Upside to Avg. PT-14.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 26, 2026JP MorganChris SchottReinstatesOverweight$22
Aug 3, 2026UBSAshwani VermaPT RaiseBuy$23→$25
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target

JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
Benzinga Newsdesk

PRO
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23

UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $16

Barclays analyst Glen Santangelo maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and raises the price target from $15 to $16.
Benzinga Newsdesk

PRO
UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19

UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $17

Truist Securities analyst Les Sulewski maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $15 to $17.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved